 Shares of Momenta Pharmaceuticals Inc. rocketed 69 into record territory in premarket trading Wednesday, after the biotechnology company announced an agreement to be acquired by Johnson Johnson in a deal valued at 6.5 billion. Under terms of the deal, JJ will pay 52.50 for each Momenta share outstanding, representing a 70.4 premium to Tuesdays closing price of 30.81. JJs stock gained 0.2 ahead of the open. The deal is expected to close in the second half of 2020. JJ said the acquisition provides its Janssen Pharmaceuticals business an opportunity to broaden its leadership in immune-mediated diseases and expand into the autoantibody-driven disease business. The deal includes full global rights to Momentas nipocalimab, a clinically validated anti-FcRn antibody, which allows Janssen to reach more patients by pursuing indications across many autoimmune diseases. Momentas stock has soared 56.2 year to date through Tuesday, while JJ shares have gained 2.9 and the SP 500 has advanced 4.9. 